TP53 and neoplasm: In addition, MDM2 contributes to tumorigenesis in a MYCN-driven transgenic mouse model for neuroblastoma, and its haploinsufficency reduces MYCN-driven tumor incidence and inhibits tumor growth via p53-mediated apoptosis (Chen et al., 2009).